T1	Participants 631 782	localized prostate cancer with an elevated prostate-specific antigen (PSA) < or = 100 ng/mL and an estimated risk of lymph node (LN) involvement of 15%
T2	Participants 784 853	Between April 1, 1995, and June 1, 1999, 1,323 patients were accrued.
T3	Participants 1644 1689	patients with a risk of LN involvement of 15%
